How Has the Diabetic Gastroparesis Treatment Market Evolved Historically and What is its Current Size?
The diabetic gastroparesis treatment market has seen considerable growth due to a variety of factors.
•The market size for treating diabetic gastroparesis has seen a consistent increase in recent years. It is projected to escalate from $3.89 billion in 2024 to $4.07 billion in 2025, with a compound annual growth rate (CAGR) of 4.5%.
The growth experienced during the historical period is a result of rising diabetes incident rates, restricted treatment alternatives, heightened awareness and diagnoses, and advancements in healthcare infrastructure.
What is the Forecasted Market Size and CAGR for the Diabetic Gastroparesis Treatment Market?
The diabetic gastroparesis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, the diabetic gastroparesis treatment market is anticipated to witness robust expansion. The market is projected to reach $5.13 billion by 2029, progressing at a compound annual growth rate (CAGR) of 6.0%.
Factors such as precision medicine and personalized therapies, an expanding diabetic patient base, intensified research and development activities, and a shifting regulatory landscape contribute to the growth during the forecasted period. Significant market trends for the forecast period include advancements in treatment technologies, the emergence of new therapies, emphasis on symptom management, the introduction of telemedicine and remote monitoring, and interventions in the gut microbiome.
What Are The Primary Growth Drivers In The Diabetic Gastroparesis Treatment Market?
The anticipated surge in diabetes cases worldwide is predicted to drive the expansion of the diabetic gastroparesis treatment market. The prevalence of diabetes indicates the ratio or percentage of people diagnosed with diabetes at a given time. Diabetic gastroparesis treatment mainly targets the management of symptoms and complications linked to this condition, a frequent diabetes-related complication. For instance, The British Diabetic Association, a UK-based diabetes charity, reported in April 2023 that 4.3 million individuals in the UK are living with diabetes. Additionally, over 2.4 million individuals in the country are at a raised risk of developing type 2 diabetes, with registration numbers reaching 148,951 in 2021-22. As such, the rising prevalence of diabetes is fuelling the expansion of the diabetic gastroparesis treatment market.
What Is The Segmentation Of The Global Diabetic Gastroparesis Treatment Market?
The diabetic gastroparesis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery
2) By Route Of Administration: Oral, Injectables
3) By Indication: Compensated Gastroparesis, Gastric Failure
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Prokinetic Agents, Antiemetics, Antidepressants, Other Pharmacological Therapies
2) By Surgery: Gastric Electrical Stimulation, Surgical Procedures For Gastric Drainage, Other Surgical Interventions
Pre-Book The Diabetic Gastroparesis Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Diabetic Gastroparesis Treatment Market Landscape?
The increasing development of fresh medications is a primary trend gaining traction in the diabetic gastroparesis treatment market. Prominent businesses in this market are introducing innovative products to maintain their market presence. For instance, in June 2023, the U.S. Food and Drug Administration, an American federal agency, sanctioned two drugs that have been previously used for treating type 2 diabetes in adults, for usage in children aged ten or above. The approval of Empagliflozin (Jardiance) and Synjardy (Empagliflozin and Metformin Hydrochloride) marks the introduction of a new category of drugs for children suffering from type 2 diabetes. Synjardy, which comprises empagliflozin and metformin hydrochloride, is employed to achieve improved glycemic regulation in patients with type 2 diabetes. Synjardy, by uniting two disparate mechanisms, provides more extensive blood sugar control compared to using any one medication independently.
Who Are the Key Players in the Diabetic Gastroparesis Treatment Market?
Major companies operating in the diabetic gastroparesis treatment market include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Ipca Laboratories Ltd.
• Abbott Laboratories
• AstraZeneca plc
• Medtronics plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Janssen Global Services LLC
• Boston Scientific Corporation
• Fresenius Kabi AG
• Bausch Health Companies Inc.
• Salix Pharmaceuticals Inc.
• Ironwood Pharmaceuticals Inc.
• Wockhardt Ltd.
• ANI Pharmaceuticals Inc.
• Endologic LLC
• Vanda Pharmaceuticals Inc.
• Rhythm Pharmaceuticals Inc.
• Theravance Biopharma Inc.
• Neurogastrx Inc.
• Evoke Pharma Inc.
• CinRx Pharma LLC
What are the Regional Insights into the Diabetic Gastroparesis Treatment Market?
North America was the largest region in the diabetic gastroparesis treatment market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
